These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32952973)

  • 1. Prognostic Significance of Transcript-Type
    Molica M; Abruzzese E; Breccia M
    Mediterr J Hematol Infect Dis; 2020; 12(1):e2020062. PubMed ID: 32952973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.
    Ercaliskan A; Eskazan AE
    Cancer; 2018 Oct; 124(19):3806-3818. PubMed ID: 29694669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
    Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
    Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre.
    Qin YZ; Jiang Q; Jiang H; Lai YY; Shi HX; Chen WM; Yu L; Huang XJ
    Br J Haematol; 2018 Sep; 182(5):693-700. PubMed ID: 29974949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of major
    Genthon A; Nicolini FE; Huguet F; Colin-Gil C; Berger M; Saugues S; Janel A; Hayette S; Cohny-Makhoul P; Cadoux N; Cayuela JM; Campos L; Guyotat D; Flandrin-Gresta P
    Oncotarget; 2020 Jun; 11(26):2560-2570. PubMed ID: 32655840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of
    Owojuyigbe TO; Durosinmi MA; Bolarinwa RAA; Salawu L; Akinola NO; Ademosun AA; Bosede OT
    Indian J Hematol Blood Transfus; 2020 Oct; 36(4):646-651. PubMed ID: 33100706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of BCR-ABL1 Transcript Type on Outcome in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors: A Pairwise and Bayesian Network Meta-Analysis.
    Chen K; Ruan Y; Tian K; Xiong P; Xia N; Li J; Huang W; Cao F; Chen Q
    Front Oncol; 2022; 12():841546. PubMed ID: 35223524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.
    Marcé S; Xicoy B; García O; Cabezón M; Estrada N; Vélez P; Boqué C; Sagüés M; Angona A; Teruel-Montoya R; Ferrer-Marín F; Amat P; Hernández-Boluda JC; Ibarra MM; Anguita E; Cortés M; Fernández-Ruiz A; Fontanals S; Zamora L; On Behalf Of The Grupo Español de Leucemia Mieloide Crónica Gelmc
    J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir.
    Azad NA; Shah ZA; Pandith AA; Khan MS; Rasool R; Rasool J; Aziz SA
    Asian Pac J Cancer Prev; 2018 Jun; 19(6):1479-1485. PubMed ID: 29936718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib.
    Pagnano KBB; Miranda EC; Delamain MT; Duarte GO; de Paula EV; Lorand-Metze I; de Souza CA
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):728-733. PubMed ID: 28822797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response.
    Marcé S; Méndez A; Xicoy B; Estrada N; Cabezón M; Sturla AL; García MR; Angona A; Amat P; Escribano Serrat S; Scalzulli E; Morgades M; Senín A; Hernández-Boluda JC; Ferrer-Marín F; Anguita E; Cortés M; Plensa E; Breccia M; García-Gutierrez V; Zamora L;
    J Clin Med; 2024 Jan; 13(3):. PubMed ID: 38337473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients.
    Arun AK; Senthamizhselvi A; Mani S; Vinodhini K; Janet NB; Lakshmi KM; Abraham A; George B; Srivastava A; Srivastava VM; Mathews V; Balasubramanian P
    Int J Lab Hematol; 2017 Jun; 39(3):235-242. PubMed ID: 28035733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of response to imatinib therapy in patients with chronic myeloid leukemia with e13a2 and e14a2 transcripts of BCR/ABL1 gene.
    Dmytrenko IV; Fedorenko VG; Shlyakhtychenko TY; Sholoyko VV; Lyubarets TF; Malinkina TV; Dmytrenko OO; Balan VV; Kravchenko SM; Martina ZV; Tovstogan AO; Minchenko JM; Dyagil IS
    Probl Radiac Med Radiobiol; 2015 Dec; 20():328-40. PubMed ID: 26695912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal Response in a Patient With CML Expressing
    Manzella L; Tirrò E; Vitale SR; Puma A; Consoli ML; Tambè L; Pennisi MS; DI Gregorio S; Romano C; Tomarchio C; DI Raimondo F; Stagno F
    In Vivo; 2020; 34(3):1481-1486. PubMed ID: 32354950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical presentation of patients with chronic myeloid leukemia in chronic phase-Case report.
    Ramdohr F; Fabarius A; Maier B; Bretschneider D; Jauch A; Monecke A; Metzeler KH; Janssen JWG; Schlenk RF; Kayser S
    Front Oncol; 2022; 12():960914. PubMed ID: 36106102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
    Rostami G; Hamid M; Jalaeikhoo H
    Gene; 2017 Sep; 627():202-206. PubMed ID: 28627443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia.
    Su YJ; Kuo MC; Chen TY; Wang MC; Yang Y; Ma MC; Lin TL; Lin TH; Chang H; Teng CJ; Hsiao PC; Chen CC; Wang PN; Shih LY
    Cancer Sci; 2022 Oct; 113(10):3518-3527. PubMed ID: 35869805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review.
    Piedimonte M; Ottone T; Alfonso V; Ferrari A; Conte E; Divona M; Bianchi MP; Ricciardi MR; Mirabilii S; Licchetta R; Campagna A; Cicconi L; Galassi G; Pelliccia S; Leporace A; Lo Coco F; Tafuri A
    BMC Cancer; 2019 Jan; 19(1):50. PubMed ID: 30630459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and Clinical Implications of a Novel
    Stella S; Massimino M; Tirrò E; Vitale SR; Accurso V; Puma A; Pennisi MS; DI Gregorio S; Romano C; DI Raimondo F; Siragusa S; Manzella L
    Anticancer Res; 2019 Dec; 39(12):6965-6971. PubMed ID: 31810968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.